
FibroGen (FGEN) Stock Forecast & Price Target
FibroGen (FGEN) Analyst Ratings
Bulls say
FibroGen Inc. is positioned for a positive financial outlook due to the anticipated rPFS improvements from its therapy FG-3246, which could enhance its competitive stance in the market. The company's financial health is further bolstered by an expected extension of its cash runway and a significant revenue stream from roxadustat, reducing reliance on dilutive capital raises for its R&D efforts. As of the end of the year, FibroGen reported $51 million in cash, in addition to an upcoming $75 million from the sale of FibroGen China to AstraZeneca, strengthening its overall financial standing amidst challenging macroeconomic conditions.
Bears say
FibroGen Inc faces significant risks that could hinder its financial performance, including the potential for failed or inconclusive clinical trials that could stall product development. The company also grapples with the challenge of securing adequate funding, which is crucial for progressing its product candidates and may lead to dilutive capital raises. Additionally, the lack of commercial success in its therapeutic offerings contributes to a negative outlook, exacerbated by concerns surrounding the risk of delisting from stock exchanges.
This aggregate rating is based on analysts' research of FibroGen and is not a guaranteed prediction by Public.com or investment advice.
FibroGen (FGEN) Analyst Forecast & Price Prediction
Start investing in FibroGen (FGEN)
Order type
Buy in
Order amount
Est. shares
0 shares